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Abstract 
Background: Genetic factors play an important role in susceptibility to methamphetamine dependency. In this line, 
protein that interact with C-kinase-1 (PICK1) and brain-derived neurotrophic factor (BDNF) genes are linked to meth-
amphetamine dependence (substance use disorder). Thus, in a case–control study, we investigated the association 
between polymorphisms of PICK1 and BDNF genes and methamphetamine dependence in an Iranian population.
Methods: Total of 235 cases and 204 controls were recruited in a period between 2015 to 2018. The PICK1-rs713729, 
-rs2076369 and BDNF-rs6265 genotypes were determined via ARMS-PCR assay. Statistical analysis was performed, 
using SPSS 20.0, PHASE 2.1.1 program as well as SNP Analyzer 2.0.
Results: In the present study, two polymorphisms including PICK1-rs713729 (OR 1.38 (CI 1.08–1.52; P-value 0.004) 
in multiplicative and dominant models, and PICK1-rs2076369 (OR 1.31 (CI 1.10–1.56; P-value 0.002) in multiplicative, 
dominant and co-dominant models were associated with the risk of methamphetamine abuse. Moreover, haplotype 
analysis showed a significant association of haplotype AG (OR 2.50 (CI 1.50–4.16; P-value 0.0002) in dominant, recessive 
and co-dominant models, and haplotype TT (OR 0.67 (CI 0.50–0.91; P-value 0.009) in dominant and co-dominant mod-
els with the risk of methamphetamine abuse. None of the polymorphisms in this study had a high level of linkage 
disequilibrium.
Conclusion: Our findings indicate that the PICK1 gene polymorphism might affect the risk of methamphetamine 
dependency in our population.
Keywords: Addiction, Drug abuse, Substance dependence, Substance use disorder (SUD), Dopamine pathway, 
Glutamate pathway, Variations, And polymorphisms
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Background
Methamphetamine is the most extensively abused ille-
gal drug and this is a growing global problem [1–3]. 
Many changes occur in the human brain as a result of 
methamphetamine abuse [4]. Methamphetamine leads 
to the release of synaptic dopamine, which might be a 
reason for the increased addiction [4]. In this context, 
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methamphetamine can have neurotoxic effects on dopa-
minergic neurons and also contribute to changes in 
another neurotransmitter system, particularly glutamate 
[5, 6]. Glutamate-mediated excitotoxicity is the major 
mechanism by which methamphetamine damages the 
central nervous system (CNS) [7, 8]. Moreover, the pri-
mary target of methamphetamine is the dopamine trans-
porters, which remove dopamine from the extracellular 
space at the synapse and controls dopamine signals [9]. 
The function and surface availability of the dopamine 
transporter are regulated via different cellular mecha-
nisms [10, 11]. Additionally, it was stated that the density 
of dopamine transporter is low in the caudate/putamen 
of methamphetamine abusers, suggesting that the long-
term use of methamphetamine results in damage to 
dopaminergic neurons [12, 13].
Several factors are involved in methamphetamine 
abuse. In this line, genetic factors play an important role 
in susceptibility to the use of methamphetamine [1–3]. 
The dopamine transporter, polymorphisms have been 
shown to be a risk factor for prognosis of prolonged-type 
methamphetamine psychosis, such as a single nucleotide 
polymorphism (SNP) [14, 15]. Moreover, in a system-
atic review, Bousman et  al. showed that several genes 
are involved in methamphetamine-related disorders. It 
has been shown that three genes including catechol-O-
methyltransferase (COMT), gamma-aminobutyric acid 
type A receptor subunit alpha1 (GABRA1) and dopa-
mine receptor D4 (DRD4), nine genes including, brain-
derived neurotrophic factor (BDNF), arrestin beta 2 
(ARRB2), cytochrome P450 2D6 (CYP2D6), glutathione 
S-transferase mu 1 (GSTM1), glycine transporter-1 
(GLYT1), glutathione S-transferase P1 (GSTP1), solute 
carrier family 22 member 3 (SLC22A3), prodynorphin 
(PDYN), and protein interacting with C kinase (PICK1), 
two genes including gamma-aminobutyric acid receptor 
subunit gamma-2 (GABRG2) and v-akt murine thymoma 
viral oncogene homolog 1 (AKT1) seem to be associated 
with methamphetamine abuse or dependence in Japanese 
and Han-Chinese populations [15]. It is indicated that 
the genetic epidemiology of methamphetamine abuse 
is very complex. There is an association between PICK1 
gene and drug addiction, such as methamphetamine 
abuse [16]. In this respect, the PICK1 gene is mapped to 
chromosome 22q13.1 [17]. Interestingly, PICK1 inter-
acts with dopamine transporter, which leads to the clus-
tering of dopamine transporter on the cell surface and 
subsequently the improvement of dopamine transporter 
uptake activity [16, 18].
Furthermore, BDNF-rs6265 is a functional SNP, 
which affects drug dependency [19]. BDNF gene is 
mapped to chromosome 11p. It was found that BDNF-
rs6265 (Val66Met) SNP is linked to susceptibility to 
methamphetamine dependence in a Thai and Malaysian 
population [20–22]. In this respect, BDNF proteins are 
involved in the regulation of synaptic transmission as well 
as the process underlying substance use disorder (SUD) 
[23]. BDNF was shown to support the survival and pro-
tection of dopaminergic neurons following methamphet-
amine administration in mice [6]. The functional effects 
of SNPs, which are linked to SUD, are often unclear; 
hence, more investigations are required on different 
populations to define how these variants influence gene 
expression and function. In this case, worldwide partici-
patory attempts are warranted to promote the accessi-
bility of large population-based datasets/samples and to 
increase the feasibility of genetic association studies [15]. 
On the other hand, a systematic review by Alam-Mehr-
Jerdi et al. indicated that the state of methamphetamine 
abuse requires further research on the epidemiology and 
health-related implications in Iran [24]. Therefore, we 
aimed to investigate the association between PICK1 and 
BDNF main SNPs and methamphetamine dependence 
(substance use disorder (SUD)) in a cohort of Iranian 
individuals.
Methods
The aim, design and setting of the study
This case–control study involved 235 cases (with meth-
amphetamine dependence (SUD)) and 204 gender-
matched controls (healthy individuals). In our study, 
SUD was recognized by the 11 criteria. The 11 criteria are 
divided into four categories of behavior, such as impaired 
control, social impairment, risky use and pharmacologi-
cal indicators (tolerance and withdrawal) related to the 
substance use (Table 1) [25, 26].
The PICK1-rs713729, PICK1-rs2076369 and BDNF-
rs6265 genotypes were analyzed by amplification 
refractory mutation system-polymerase chain reaction 
(ARMS-PCR) assay. Subsequently, statistical analysis 
was performed, using SPSS 20.0 (IBM Inc., Chicago, IL, 
USA), PHASE 2.1.1 program as well as SNP Analyzer 2.0.
The characteristics of participants
Study population and clinical data
This study was performed in accordance with the Dec-
laration of Helsinki (1964) and its subsequent amend-
ments. Moreover, approval was obtained from the local 
Ethics committee of Mashhad University of Medical 
Sciences (IR.MUMS.fm.REC.1394.421), 439 blood sam-
ples were collected from 204 controls and 235 cases 
from Mashhad, Iran from 2015 to 2018. After explain-
ing the study objectives, a written informed consent 
was obtained from all participants. A questionnaire was 
used to collect demographic and other essential informa-
tion from all participants (Table 2). The selection proce-
dure included confirmed urine test (addiction test) and 
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also the availability of complete patient’s follow-up data. 
Moreover, healthy participants, individually matched on 
age, were recruited from the Health Examination Centre 
who were receiving routine medical examinations.
Description of materials
Blood collection and DNA extraction
In order to extract the DNA, approximately 10 millilitres 
(ml) of peripheral blood was obtained from all partici-
pants and immediately subdivided into tubes containing 
sterile ethylene diamine tetra acetic acid (EDTA) [27]. 
DNA extraction from whole blood was extracted using 
salting-out technique. Then, the extracted DNA was 
quantified by the ratio of absorbance at 260  nm (nm) 
and 280  nm  (A260/280) via BioTek™ Epoch™ Microplate 
Spectrophotometer (Winooski, VT, USA,) as well as via 
gel electrophoresis and finally stored at -20 °C until used.
Target single nucleotide polymorphisms (SNPs) 
determinations (Marker selection)
In this study, the SNPs were selected using available SNPs 
databases and published articles. Such articles  examined 
intron and exon SNPs, which might alter the affinity of 
PICK1-rs713729, PICK1-rs2076369 and BDNF-rs6265 to 
methamphetamine dependence (SUD) (Table 3). Moreo-
ver, potential functional SNPs were included in order 
to meet the following criteria: minor allele frequency 
(MAF) > 0.05 (5%), heterozygosity > 0.15 (15%) and also 
validated SNPs in articles and databases. Furthermore, 
in order to inhibit redundancy in SNPs genotyping, SNPs 
that are not located in strong linkage disequilibrium (LD) 
were chosen.
Table 1 Criteria for substance use disorders (SUD)
*In the present study, substance use disorders (SUD) is recognized by these 11 criteria
Num Categories of behaviour Criteria for Substance Use Disorders (SUD)*
1 Impaired control Used larger amounts or longer: Taking the drug in greater quantities or over prolonged periods of time
2 Repeated attempts to control use and/or quit: Wanting to cut or avoid using the substance, but they haven’t been 
successful
3 Much time spent using: Spending a lot of time to get, using, or recover from substance using
4 Craving: Cravings and encourages the substance to be used
5 Social impairment Activities given up to use: Not able to do what you can do at home, at work, or at school that you once liked because 
of substance use
6 Social or interpersonal problems related to use: Continuing to use, even though it creates issues in your relationships 
or conflicts with others
7 Neglected major roles to use: Giving up and refusing to perform significant social, occupational or recreational func-
tions as a result of substance use
8 Risky use Hazardous use: Using substances again and again, including though you or others are in danger
9 Social or interpersonal problems related to use: Continuing to use, even though you know that you have a physical or 
psychological condition which may have been triggered or exacerbated by the substance
10 Pharmacological indicators Tolerance: Need more substance to have the effect you like
11 Withdrawal: Development of withdrawal symptoms and signs of withdrawal, which can be eased by taking more of 
the substance
Table 2 Demographic and clinical characteristics of controls and methamphetamine dependence (SUD)
*Significant P-value < 0.05. SD: Standard deviation




Gender Female 38.9% 35.7% P < 0.001
Male 68.1% 64.3%
Age (SD) 31.96 (8.44 ± 0.58) 38.91 (9.11 ± 0.68) P = 0.423
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Genotyping
To determine the genotype frequency of PICK1-rs713729, 
PICK1-rs2076369 and BDNF-rs6265 an ARMS-PCR 
method was used. Specific primers for PCR amplification 
were designed via web tools, such as Primer1 and also 
WASP (web-based allele-specific primer designing tool) 
[28].
PCR amplifications for PICK1-rs713729, PICK1-
rs2076369 and BDNF-rs6265 were conducted in a 
10–15  µl (μl) volume per reaction, containing 3  µl Taq 
2 × master mix (Ampliqon, Germany), 10  µM of each 
primer and 100 nanogram (ng) DNA. Moreover, the 
specific primers used to detect PICK1-rs713729, PICK1-
rs2076369 and BDNF-rs6265 SNPs are listed in Table 4. 
For PICK1-rs2076369, we also used betaine (Ampliqon, 
Germany) as an enhancer in PCR.
The ARMS-PCRs condition for each primer is as fol-
lows, Table  5. In general, initial denaturation at tem-
perature 94 °C for five minutes, then 35 cycles including 
denaturation at 94 °C for 25 s, annealing at alternative °C 
for 25 s (based on each primer), an elongation at 72 °C for 
30 s followed by 72 °C for seven minutes as the final elon-
gation step (Table 5).
Absence or presence of mutant or normal PCR prod-
ucts were detected via gel electrophoresis in 3% aga-
rose gel by ultraviolet (UV) trans illuminator (Gel Doc; 
U:Genius).
Statistical analysis
A Hardy–Weinberg equilibrium (HWE) method was 
used to evaluate the differences in data for statistical 
significance. HWE assumption was investigated by the 
Pearson χ2 distribution with 1 degree of freedom. Allele 
and genotype frequencies were calculated, and the dif-
ferences between groups were evaluated by Chi-squared 
tests. Then, the association between methamphetamine, 
risk factors and alleles/genotypes was evaluated by binary 
logistic regression, estimating Odds ratios (ORs) and also 
95% confidence intervals (CIs). Three logistic regression 
models were used to analyse the SNPs, using different 
genetic models (additive, dominant, and recessive). For 
the analysis of SNP-SNP interactions, an adjusted logistic 
regression model was used to estimate the multiplicative 
Table 3 Characteristics of the investigated polymorphisms in this study
PICK1: Protein that interact with C-kinase-1; BDNF: Brain-derived neurotrophic factor; Val66Met (also called rs6265): Met: Methionine and Val: Valine; METH: 
Methamphetamine; bp: Base pairs




Allele Function Haplotype 
distance 
(bp)
rs713729 PICK1 Non-coding 22:38,059,462 Intron 3 1 T > A Intron variant 8183
rs2076369 PICK1 Non-coding 22:38,067,645 Intron 4 1 T > G Intron variant
rs6265 BDNF NP_001137277.1:p.
Val66Met
11:27,658,369 Exon 4 1 C > T Missense -
Table 4 Primer sequences used for genotyping in ARMS-PCR
Expected product size in bps depending on the SNPs. FO: Forward outer primer; FI: Forward inner primer; RI: Reverse inner primer; RO: Reverse outer primer; bp: Base 
pairs; ARMS-PCR: Amplification refractory mutation system-polymerase chain reaction; SNP: Single nucleotide polymorphism
SNPs Primers Sequences Primer Length (bp) PCR 
products 
(bp)
rs6265 FO CTA CAG TTC CAC CAG GTG AGA AGA GTG 27 400
RO ATG GAC ATG TTT GCA GCA TCT AGG TA 26
FI (c) TGG TCC TCA TCC AAC AGC TCT TCT ATaAC 29 253
RI(t) TTG GCT GAC ACT TTC GAA CcCA 22 201
rs713729 FO CTT TCT AGC GGA ATC CCG ACT GTG 24 407
RO CAG TGA AAA AGC AAA CCA GGA CAC TG 26
FI(a) CTT CTC ATT CTT GAG GTC TGA CCC ACA 27 196
RI(t) AGG TGG TCA GAA AGC CCC TCAGA 23 265
rs2076369 FO CAT GTT GCC CAA GCT GGT CTC AAA CTC 27 299
RO CTG GAC ACC CGT AAC TGC TCT GAC C 35
FI(g) AGG AGT CTC AGT CCA GAA CAG TCT TGACG 29 191
RI(t) CTC CAC ACC CTG AGC CCC TTC TCA 24 165
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interaction effect of the SNPs, located on the same hap-
lotype. P-value = 0 < 0.05 was considered to be statistically 
significant. SPSS 20.0 (Inc., Chicago, IL, USA), PHASE 
program as well as SNP Analyser 2 software were used 
for further statistical analysis [29].
Haplotype analysis
Haplotypes were generated and assembled from the 
genotyped data by PHASE program, to reconstruct hap-
lotypes, and SNP Analyzer 2 software [29, 30]. In the pre-
sent study, P-values of less than 0.05 were considered to be 
statistically significant. Moreover, Bonferroni correction 
was also used to account for multiple testing; thus, a two-
tailed P-value < 0.016 (=0.05/3 SNPs) was considered to be 
statistically significant in the present study.
Results
Identification of single nucleotide polymorphisms (SNPs) 
and association studies
There were no significant associations between BDNF-
rs6265 and the risk of methamphetamine dependence 
(SUD). On the contrary, a significant association was 
observed between two SNPs and the risk of metham-
phetamine abuse including PICK1-rs713729 (OR 1.38 (CI 
1.08–1.52; P-value 0.004) in multiplicative and dominant 
models, and PICK1-rs2076369 (OR 1.31 (CI 1.10–1.56; 
P-value 0.002) in multiplicative, dominant and co-dom-
inant models (Table  6). Moreover, haplotype analysis 
showed that specific haplotypes related to these SNPs 
were associated with methamphetamine dependence 
(SUD). In this line, analysis of  PICK1-rs713729 and 
PICK1-rs2076369 haplotypes in our population  showed 
that the  haplotype AG (OR 2.50 (CI 1.50–4.16; P-value 
0.0002) in dominant, recessive and co-dominant models 
and haplotype TT (OR 0.67 (CI 0.50–0.91; P-value 0.009) 
in dominant model and co-dominant model had a sig-
nificant association with the risk of methamphetamine 
dependence SUD) (Table 7).
Distribution of single nucleotide polymorphisms (SNPs)
The frequencies of the genotypes with high-quality gen-
otype call were as follows: PICK1-rs713729 “TT” 174 
(77.67%), “AT” 33 (14.73%), and “AA” 17 (7.58%) among 
cases and “TT” 168 (87.95%), “AT” 17 (8.90%) and “AA” 
6 (3.14%) among controls; PICK1-rs2076369 “GG” 
117 (52.23%), “GT” 80 (35.71%) and “TT” 27 (12.05%) 
among cases and 70 (36.08%), 100 (51.54%), 24 (12.37%) 
and among controls, respectively. Moreover, BDNF-
rs6265 genotype frequencies were: “CC” 161 (72.52%), 
“CT” 55 (24.77%) and “TT” 6 (2.70%) among cases and 
142 (73.57%), 48 (24.87%) and 3 (1.55%) among con-
trols, respectively.  Table  7  shows the  conferred risk by 
each haplotype. In this study, two haplotypes, AG and 
TT were significantly different between the normal and 
methamphetamine dependence (SUD) individuals. The 
prevalence of TT haplotype in the case group (27%) was 
lower than that of the normal individuals (34%), and the 
frequency of the AG haplotype in the methamphetamine 
dependence (SUD) individuals was higher (12%) than 
that (3%) of the normal individuals (Additional file  1: 
Table 1). We also examined whether the three SNPs were 
in LD. In this line, there was no strong LD between these 
SNPs (Additional file 2: Table 1).
Table 5 The ARMS-PCRs condition for targeted SNPs
FO: Forward outer primer; FI: Forward inner primer; RI: Reverse inner primer; RO: Reverse outer primer; TM: Temperature; Min: Minute; S: Seconds; °C: Centigrade; 
ARMS-PCR: Amplification refractory mutation system-polymerase chain reaction; SNP: Single nucleotide polymorphism
SNPs Primers First Denaturation 35 cycles Last extension
Tm°C Min Denaturation Annealing Extension Tm°C Min
Tm°C Min Tm°C Min Tm°C Min








rs2076369 FO 64 25 s 30 s 5 min
RI(t)
FI(g) 67 30 s
RO
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Discussion
The SUD is a persistent relapsing disorder with harm-
ful consequences [31]. In this respect, the brain reward 
system such as mesocortical dopamine system is the 
common feature of this disorder [32, 33]. Furthermore, 
abnormal dopamine and glutamate systems are asso-
ciated with the pathophysiology of SUD and depend-
ency. However, the development of drug dependency 
is affected via factors, such as pharmacological effects 
on mental status, environmental and individual factors, 
such as genetics. In this respect, genetic factors are sug-
gested to have a greater effect on drug dependency. It 
was shown that drugs abuse and addiction cause dopa-
mine and opioid peptides to be released into the ventral 
striatum, which causes “high” sensation in abusers [33, 
34].
The use of methamphetamine has become a serious 
health concern in Iranian methadone dependent patients 
[24, 35]. In Iran, it is used to improve sexual perfor-
mance and promote physical energy due to its stimu-
lating effects [36]. It is shown that methamphetamine 
abuse has surged from 3.9% amongst both genders in 
2007 to 60.3% for men in 2014 and 89.5% for women in 
2015–2016. Remarkably, the frequency of methampheta-
mine dependence amongst female methadone depend-
ent patients in the Iranian population was higher. This 
dependency has been linked to multiple health issues in 
the social and health contexts of both genders, particu-
larly women [35].
Showing a possible association between PICK1-
rs713729 and PICK1-rs2076369 in the PICK1 gene pro-
moter with methamphetamine dependence were the 
key findings of the present study. Consistent with our 
study, Matsuzawa et  al. showed that PICK1-rs713729 
and PICK1-rs2076369 were significantly associated 
with methamphetamine abuse in a Japanese popula-
tion (Table 8). Additionally, they revealed that PICK1-
rs713729 was linked to those with spontaneous relapse 
of psychosis [16]. Moreover, PICK1 gene was reported 
as the beginning of methamphetamine addiction, worse 
Table 6 Analysis based on different genetic models
PICK1: Protein interacting with C-kinase-1; BDNF: Brain-derived neurotrophic factor; SNP: Single nucleotide polymorphism. OR: Odds ratio; CI: Confidence interval; 
P-values were obtained from Chi-square tests; *Significant of P-value < 0.05; The association between methamphetamine, risk factors and alleles/genotypes was evaluated 
by binary logistic regression, estimating ORs and also CIs. Note: Significant P-value in bold; Bonferroni corrected P-value is 0.016
SNP number Gene Position Genetic models OR 95%CI P-value* Bonferroni 
correction
P-value
rs713729 PICK1 22: 38,059,462 Multiplicative 2.12 1.34–3.36 0.001 0.003
Dominant 2.08 1.21–3.57 0.007 0.020
Recessive 2.51 0.97–6.52 0.05 0.149
Co-dominant 2.71 1.04–7.06 0.02 0.061
rs2076369 PICK1 22: 38,067,645 Multiplicative 0.68 0.05–0.91 0.009 0.028
Dominant 0.51 0.34–0.76 0.0008 0.003
Recessive 0.92 0.51–1.67 0.806 -
Co-dominant 0.64 0.34–1.21 0.003 0.008
rs6265 BDNF 11: 27,658,369 Multiplicative 1.09 0.74–1.61 0.65 -
Dominant 1.05 0.68–1.63 0.81 -
Recessive 1.75 0.43–7.13 0.64 -
Co-dominant 1.76 0.43–7.18 0.89 -
Table 7 Haplotype analysis based on  different genetic 
models
H1: TG; H2: TT; H3: AT; H4: AG; OR: Odds ratio; CI: Confidence interval; P-values were 
obtained from Chi-square tests. * Significant of P-value < 0.05; Significant P-value in 
bold
Genetic models Haplotype P-value
* OR Lower CI Higher CI
Multiplicative H3 0.0002 2.5 1.502 4.161
H2 0.009 0.678 0.505 0.91
H1 0.742 1.047 0.794 1.382
H4 0.745 0.84 0.292 2.416
Dominant H2 0.001 0.532 0.358 0.79
H3 0.007 2.123 1.217 3.704
H1 0.735 0.924 0.582 1.466
H4 0.762 0.838 0.266 2.643
Recessive H3 0.003 11.569 1.499 89.293
H1 0.436 1.175 0.782 1.766
H4 0.555 0.842 0.052 13.549
H2 0.651 0.867 0.466 1.611
Co-dominant H3 0.004 12.331 1.595 95.316
H2 0.006 0.627 0.326 1.206
H1 0.571 1.044 0.620 1.757
H4 0.840 0.838 0.052 13.492
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prognosis as well as spontaneous relapse [37]. PICK1 
is involved in the targeting and localization of synaptic 
membranes proteins and also in the surface of dopa-
mine transporter clustering on the cell surface [18, 38]. 
This clustering leads to an increase of dopamine trans-
porter uptake activity. Thus, PICK1 expression levels 
can alter the role of the dopamine transporter and can 
affect the pathogenesis of methamphetamine abuse/
dependency [16]. Moreover, the interactions of PICK1 
with α-amino-3-hydroxy-5-methyl-4-isoxazole pro-
pionate (AMPA) receptors, metabotropic glutamate 
receptors and D-serine synthesizing enzyme have been 
shown and might be implicated in the pathogenesis of 
drug-related disorders [39–42]. Further studies are still 
required to show the direct association of these pro-
teins in the pathogenesis of methamphetamine abuse.
Based on previous studies, it was reported that gene 
variations, which are associated with glutamatergic 
and serotonin systems explain differences in SUD and/
or dependency risk between individuals. It is indicated 
that glutamate-related genes influence the risk of SUD 
and/or dependency. The glutamate receptor genes were 
suggested to interact with BDNF by BDNF- tropomyo-
sin kinase B (TrKB) transduction signaling cascade. 
BDNF is a neurotrophic factor, which is involved in the 
expansion, maintenance and survival of dopaminergic 
neurons in CNS [43].
In the present study, no association was found between 
BDNF-rs6265 and the risk of methamphetamine depend-
ence (SUD) in our population. This finding is consistent 
with the result of methamphetamine dependent male 
Caucasian individuals, which showed no association 
in 193 non-psychotic males (117 methamphetamine-
dependent cases and 76 controls) [44]. However, Cheng 
et  al. showed that there was an association between 
methamphetamine-dependency and BDNF gene in 103 
Table 8 The association studies regarding  methamphetamine and  BDNF/PICK1 gene polymorphisms 
in the methamphetamine abusers and controls
SNP: Single nucleotide polymorphism; PICK1: Protein that interact with C-kinase-1; BDNF: Brain-derived neurotrophic factor; Val66Met (also called rs6265): Met: 
Methionine and Val: Valine; METH: Methamphetamine; Ref: References
Gene-SNP Ethnicity Sample size Result Refs
Meth Normal
BDNF-Val66Met Chinese 200 219 No significant differences in genotype and allele. The Met 
allele was associated with earlier age onset of METH use
[52]
BDNF-rs16917204, rs16917234, rs2030324 Chinese 200 219 No significant differences in genotype and allele distribu-
tions
[53]
BDNF-Val66Met Taiwanese 103 200 Significant differences in BDNF Val66Met genotype distri-
bution
[21]
BDNF-Val66Met (rs6265) Thai 100 102 Significant differences in the distribution of rs6265 geno-
type
A lower frequency of GG genotype associated with METH-
induced psychosis
[20]
BDNF promoter methylation Chinese 30 52 BDNF promoter methylation is associated with drug addic-
tion
[54]
BDNF-Val66Met Chinese 194 378 No significant differences in genotype and allele distribu-
tions
A significant positive correlation between serum BDNF and 
the delayed memory index score
[55]
BDNF-Val66Met Japanese 189 202 No significant differences were found in the frequency of 
the genotype or allele
[56]
BDNF-Val66Met Chinese 24 45 A significant distribution of the BDNF Val66Met genotype 






BDNF-Val66Met Caucasian 60 None Significantly more pretreatment days with METH use in 
females than males
A significant association between females with Val/Val 
genotype and METH use
[57]
PICK1- s737622, rs3026682, rs713729, rs2076369 Japanese 208 218 A significantly association between:
-rs713729 and METH abusers
-rs713729 and rs2076369 with spontaneous relapse of 
psychosis
[16]
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methamphetamine abusers and 122 normal controls. 
They noted that the lower 66Met carriers were linked to 
substance abuse [21]. Furthermore, Sim et  al. described 
an increase in a Chinese subgroup of Malaysian meth-
amphetamine-dependent subjects (n = 24), which was 
not found among other Malaysian ethnic groups [22]. 
The various results for this SNP might be due to differ-
ent sample sizes and also different ethnicities as well as 
genetic diversity (Table 8). It is indicated that ethnic dif-
ferences can affect the frequency of BDNF Val66Met [45, 
46].
Long-term methamphetamine-induced brain changes 
are significantly dependent on BDNF genetic variation 
[47]. Val66Met might enhance the risk of suicide behav-
ior [45]. Moreover, BDNF variations might be involved 
in methamphetamine withdrawal. BDNF levels, equal 
or less than 1,251.0  pg/ml has been stated to be linked 
to depression symptoms during methamphetamine with-
drawal [48]. BDNF Val66Met had an important effect on 
the Treatment Effectiveness Score (TES), methamphet-
amine-negative urine drug screens during treatment, 
which was higher among Val/Val Caucasian carriers [49]. 
Interestingly, there were more pretreatment days with 
methamphetamine use in females with Val/Val genotype 
than males [10]. Estrogen improves BDNF expression, 
which has implications on the release of striatal dopa-
mine caused by methamphetamine and protects against 
neurotoxicity caused by methamphetamine [50, 51]. 
Thus, females can be able to use methamphetamine more 
frequently [10].
Furthermore, there was no association between PICK1 
and BDNF gene polymorphisms in our study. That may 
be attributed to the different positions of the gene poly-
morphisms on different chromosomes [PICK1 (22q13.1) 
and BDNF (11p13–15)].
There were some limitations in our study. We did not 
investigate all the SNPs in these genes. Although, the 
sample size was large enough to detect an association 
between these SNPs and SUD in comparison with pre-
vious studies, larger sample size would strengthen the 
results. We therefore recommend further replication 
studies with larger sample size in order to validate and 
explain this association with conclusive findings.
Conclusions
Collectively, the variation in the PICK1 gene was asso-
ciated with methamphetamine dependence (SUD), 
reflecting the underlying biological mechanisms, 
which can make a bridge between pathways and 
methamphetamine dependence (SUD). Our findings 
suggest that the PICK1 gene might be involved in sus-
ceptibility to SUD in our population. These findings 
can be helpful in rehabilitation programs and psycho-
education for those who have substance dependency. 
In this case, potential genetic predictors can be used 
for individuals susceptible to SUD. All in all, under-
standing genetic variations might help to understand 
the biological mechanisms of progression, and sup-
pression of methamphetamine. In addition, our find-
ings provide the basis for future genetic research on 
the use of methamphetamine dependency and related 
neurological side effects.
Supplementary information
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